ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > More great data from PMN

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Jul 25, 2023 2:48pm

147 Views

Post# 35556399

RE:RE:RE:RE:RE:RE:RE:More great data from PMN

There's only one guarantee when it comes to PMN's share price; if it goes up, it's going right back down.

Until they get into clinicals and actually PROVE they have what they claim they have, this is our fate. And even then who knows.

One thing is for sure though, the rich will get richer.

*sigh*

<< Previous

Bullboard Posts

Next >>

Cross border trading in Canada and Australia